Gilead paid $80 million upfront to acquire global rights to Genhouse Bio’s MAT2A‑targeting synthetic‑lethal oncology candidate GH31, with up to $1.45 billion in milestones and tiered double‑digit royalties. Genhouse has cleared IND filings in China and the US and positions GH31 for rapid clinical advancement. Gilead described the deal as part of a disciplined expansion of its oncology pipeline through external innovation, emphasizing synthetic lethality as a route to target tumor dependencies. Genhouse’s broader pipeline includes PRMT5, DHX9 and HDAC6 programs, reflecting a China‑originating discovery portfolio now validated by a large pharma transaction. The acquisition underscores Big Pharma’s continued appetite for first‑ or best‑in‑class cancer assets from Asia, and the deal provides Genhouse capital and partnership to accelerate clinical development globally.